Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Montanide ISA-51 (Primary) ; Nogapendekin alfa inbakicept (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 04 Jun 2025 Planned initiation date changed to 9 Jun 2025.
- 29 May 2025 Planned initiation date changed from 28 May 2025 to 3 Jun 2025.
- 23 May 2025 Planned initiation date changed to 28 May 2025.